PCAOB and CSRC‘s Agreement on Audit Terms Could Fail - The Real Test of China ADRs Lies Ahead
China ADRs are only a part of Sino-US game, which shouldn't be looked at alone. It’s hard to reach final agreement. The trend of relisting on HKEX...
279 Views
Legend Biotech Follow-On - A Little Opportunistic. Last Deal Did Well, After a Large Correction
Legend Biotech Corp (LEGN US), a non-wholly owned subsidiary of Hong Kong-listed Genscript Biotech (1548 HK), is planning to raise up to US$250m in...
426 Views
Hutchmed China Ltd (13.HK/HCM.US) - Big but Not Strong
Li Ka-shing's original intention for Hutchmed is not on innovative drugs. Hutchmed's current pipeline also does not have core competitiveness. So,...
392 Views
The Impact of HFCAA on China ADR (China Healthcare Companies)
We analyzed the points in HFCAA that are difficult for China to accept.Such irreconcilable contradiction could lead to a trend of delisting from...
382 Views
China ADRs & HFCAA: Pace of Homecoming Listings Should Pick Up & Implications
The SEC naming 5 companies under the HFCAA put China ADRs under pressure last week. The news that the CAC had nixed DIDI's HK listing plans added...
786 Views